Clinical Trial: Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Study Status: Completed
Recruit Status: RECRUITING
Condition: Secondary Hyperparathyroidism
Study Type: INTERVENTIONAL
Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage
Brief Summary:
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT).The study consists of two phases.First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks.After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive…
Read more